Bandingkan Harga & Kinerja Multifiling Mitra Indonesia Tbk. (MFMI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Multifiling Mitra Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: Multifiling Mitra Indonesia Tbk. diperdagangkan di Rp1.300 (kapitalisasi pasar 984,86 M), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Multifiling Mitra Indonesia Tbk. jauh lebih besar — sekitar 9,4× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| MFMI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 984,86 M | 104,4 M |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Multifiling Mitra Indonesia Tbk.
PT Multifiling Mitra Indonesia Tbk (the Company) was established based on the Notarial Deed No. 157 of Misahardi Wilamarta, SH., dated July 9, 1992. MMI is a joint venture company between PT.Multipolar Corp. Tbk. and PT. Lippo Karawaci Tbk, currently serving its customers in 4-big city, Jakarta, Surabaya, Medan dan Bandung.
Selengkapnya di halaman MFMI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
